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IL-10 is an anti-inflammatory cytokine that plays a significant role in the modulation of
the immune response in many pathological conditions, including infectious diseases.
Infection with Trypanosoma cruzi (T. cruzi), the etiological agent of Chagas disease,
results in an ongoing inflammatory response that may cause heart dysfunction,
ultimately leading to heart failure. Given its infectious and inflammatory nature, in this
work we analyzed whether the lack of IL-10 hinders the anti-inflammatory effects of
fenofibrate, a PPARα ligand, in a murine model of Chagas heart disease (CHD) using
IL-10 knockout (IL-10 KO) mice. Our results show fenofibrate was able to restore the
abnormal cardiac function displayed by T. cruzi-infected mice lacking IL-10. Treatment
with fenofibrate reduced creatine kinase (CK) levels in sera of IL-10 KO mice infected
with T. cruzi. Moreover, although fenofibrate could not modulate the inflammatory
infiltrates developing in the heart, it was able to reduce the increased collagen deposition
in infected IL-10 KO mice. Regarding pro-inflammatory mediators, the most significant
finding was the increase in serum IL-17. These were reduced in IL-10 KO mice upon
fenofibrate treatment. In agreement with this, the expression of RORγt was reduced.
Infection of IL-10 KO mice increased the expression of YmI, FIZZ and Mannose Receptor
(tissue healing markers) that remained unchanged upon treatment with fenofibrate.
In conclusion, our work emphasizes the role of anti-inflammatory mechanisms to
ameliorate heart function in CHD and shows, for the first time, that fenofibrate attains
this through IL-10-dependent and -independent mechanisms.
Keywords: Trypanosoma cruzi, IL-10 knockout mice, fenofibrate, chronic chagasic cardiomyopathy, inflammatory
response
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INTRODUCTION
Infection with Trypanosoma cruzi (T. cruzi), the etiological agent
of Chagas disease, triggers both innate (1–3), and adaptive (4–
6) immune responses that aim at the control of the parasite load
both in tissues and peripheral blood [Reviewed in (7)]. However,
these mechanisms do not succeed in the complete eradication of
the parasite, which results in parasite persistence (8–12).
An ongoing inflammatory process dysregulated by yet
unknown factors, associated with unsuccessful parasite control,
leads to severe consequences in 30–40% of infected people
late during the chronic phase of which Chronic Chagasic
Cardiomyopathy (CCC), a form of dilated cardiomyopathy,
is the most frequent consequence (13, 14). Its main features
are the development of cardiac conduction system anomalies
leading to arrhythmia, microvascular alterations leading to
thromboembolism, and inflammatory processes that promote
heart muscle fibrosis. These patients may undergo heart chamber
remodeling, congestive heart failure and death (15, 16).
The inflammatory response is characterized by the
recruitment of mononuclear cells to the heart and other
tissues, and increased systemic and local inflammatory
mediators, including cytokines like IL-1β, IL-6, and TNFα
and enzymes like iNOS, involved in the production of NO,
or matrix metalloproteinases like MMP-9, that contribute to
tissue remodeling (17–19). Despite the low levels of parasite load
observed during the chronic phase of infection, its persistence
plays a crucial role to uphold the inflammatory reaction leading
to heart anomalies and remodeling (10, 20).
In this regard, the balance between the pro-inflammatory/pro-
fibrotic cytokine IL-17, mainly produced by Th17 cells (21,
22), and the anti-inflammatory/anti-fibrotic cytokine IL-10,
produced by Treg, alternatively activated macrophages and
CD5 B cells (23–25), should be considered. Overall, persistent
expression of IL-17 would promote fibrosis and tissue scar
formation in several pathological conditions, including systemic
sclerosis (26), kidney fibrosis in diabetes (27), primary biliary
cirrhosis (28), and ischemic heart failure involving ventricular
arrhythmia (29). Conversely, IL-10 has been shown to promote
the senescence of hepatic stellate cells via STAT3/p53, in a
model of Cl4C-induced fibrosis in rats (30), reduce fibrosis
during cutaneous wound healing in human and mice (31), and
ameliorate high-fat-diet atrial remodeling in C57Bl/6 IL-10 KO
mice, preventing fibrillation (32). Importantly, the regulation of
M2 macrophage polarization by IL-10 seems to be critical to
preclude the harmful outcome of scar formation in different
tissues (33, 34).
Considering the role of IL-10 in CCC, a recent work shows
that a betulinic acid derivative is able to reduce inflammation
and fibrosis, associated with a significant increase in serum
IL-10 levels, in an experimental model of chronic Chagas
disease. However, these authors do not report any changes in
the electrocardiographic or ergometry registers resulting from
treatment (35). Interestingly, it has been shown that IL-10
inhibits the production of pro-inflammatory cytokines signaled
by the NF-kB and ERK/MAPK pathways through upregulation
of SOCS3 in cardiomyocytes infected in vitro with T. cruzi (36).
Given the inflammatory nature of CCC, pharmacological
interventions focused on the control of its deleterious effects
may prove successful in ameliorating the course and outcome
of the disease. Concerning this, fibrates have emerged as
putative anti-inflammatory drugs, besides their effects to control
dyslipidemias (37). Remarkably, we recently published evidence
that fenofibrate is able to restore heart function, as assessed
by echocardiography, and reduce inflammatory mediators
expressed in the heart, as well as serum markers of heart
damage, in an experimental model of Chagas disease (38).
However, the role that fenofibrate may play in the context
of the pro/anti-inflammatory imbalance leading to pathology,
is still unclear.
In this work we study the consequences of IL-10 depletion on
the effects of fenofibrate on cardiac function, proinflammatory




Mice used in this study were bred and maintained in the animal
facility at the Instituto de Investigaciones en Microbiología y
Parasitología Medica, Universidad de Buenos Aires-CONICET.
All procedures carried out with mice were approved by the
Institutional Committee for the Care and Use of Laboratory
Animals (CICUAL, Facultad de Medicina de la Universidad de
Buenos Aires) in line with guidelines of the Argentinean National
Administration of Medicines, Food and Medical Technology
(ANMAT), Argentinean National Service of Sanity and Agrifoods
Quality (SENASA) and also based on the US NIH Guide for the
Care and Use of Laboratory Animals.
Mice
To carry out this work, BALB/c-background IL-10 knockout (IL-
10 KO) mice, homozygous for the targeted mutation Il10tm1Cgn
(Stock Number 004333; The Jackson Laboratory, United States)
(39) and wild type (WT) BALB/c mice were used.
Experimental Design
Eight-weeks old BALB/c IL-10 KO and WT male mice were
infected by intraperitoneal route with 1 × 105 bloodstream
trypomastigotes of the non-lethal K-98 clone of T. cruzi (DTU I)
(40, 41). At weeks 5 and 9 post-infection (pi), echocardiographic
studies were carried out to evaluate cardiac dysfunction. The
following scheme depicts the experimental design:
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Treatment
Mice were treated by oral gavage with fenofibrate
(100 mg/kg/day) Daunlip R©, Montpellier S.A, Argentina.
PubChem Compound Database CID = 3339, Fen, suspended
in phosphate-buffered saline (PBS) for 30 consecutive days,
since week 5 pi.
Parasitemia and Survival
Presence of parasites in blood was evaluated by the
microhematocrit method (42) at week 3 post infection (pi).
Parasitemia was analyzed weekly, using the method of Pizzi
modified by Brener (1962) (43), from week 3 pi until the end of
the experiment. Survival was observed daily, until the end of the
experiment. Parasitemia was expressed as parasites per milliliter.
Doppler Echocardiography
Transthoracic echocardiography was performed using an Acuson
Sequoia C 512 ultrasound system with a 14-MHz linear
transducer. Echocardiographic experiments were conducted
under light anesthesia (287.5 mg/kg of 2.5% sterile-filtered 2,2,2-
tribromoethanol; Sigma-Aldrich).
The two-dimensional parasternal short-axis imaging plane
was used to obtain M-mode tracings at the level of the
papillary muscles. Left ventricular (LV) internal dimensions and
LV wall thickness (LVWT) were determined at systole and
diastole using leading-edge methods and the American Society of
Echocardiography guidelines (44). End-diastolic measurements
were taken at the maximal LV diastolic dimension, and end
systole was defined as the time of the most anterior systolic
excursion of the posterior wall. Measurements were taken
from three consecutive beats for each mouse. Ejection fraction
(EF) and shortening fraction (SF) were calculated and used
as ejective indexes of systolic function. EF was estimated
from LV dimensions by the cubed method as follows: EF
(%) = [(LVEDD3-LVESD3)/LVEDD3] × 100, where LVEDD
is LV end-diastolic diameter, and LVESD is LV end-systolic
diameter. The isovolumic relaxation time (IVRT) was measured
by the Doppler-echo study (38).
Histological Studies
Hearts from untreated uninfected controls, T. cruzi-infected and
T. cruzi-infected and fenofibrate-treated IL-10 KO and WT mice
were fixed in PBS-buffered 4% paraformaldehyde and included in
paraffin after dehydration. Six non-contiguous sections (5 µm)
were stained with hematoxylin-eosin or picrosirius red for the
examination of cellular infiltrates and collagen deposits. Images
from thirty random microscopic fields (400x) were acquired
using an Eclipse E600 microscope (Nikon Inc.) equipped with a
Spot RT digital camera. Analysis was performed using the Image
J software (NIH, United States) (38).
Creatine Kinase Activity
Serum creatine kinase (CK) activity was measured in the serum
of uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-
treated IL-10 KO and WT mice using a colorimetric method
based on the photometric NADP reduction assay according to
manufacturer’s instructions (Wiener Lab, Rosario, Argentina).
Absorbance was measured at 340 nm.
mRNA Purification
Total RNA was obtained from heart tissue homogenates
using Quickzol reagent (Kalium) treated with DNAse (Life
Technologies). Total RNA was reverse-transcribed using Expand
Reverse Transcriptase (Invitrogen Corp., MA, United States),
according to manufacturer’s instructions.
Quantitative Reverse Transcription
Polymerase Chain Reaction
Quantitative reverse transcription polymerase chain reaction
(RT-qPCR) was performed using a 5 × HOT FIREPol R©
EvaGreen R© qPCR Mix Plus (ROX; Solis BioDyneCorp., Estonia)
in an Applied Biosystems 7500 sequence detector. PCR
parameters were 52◦C for 2 min, 95◦C for 15 min, and 40 cycles
of 95◦C for 30 s and 60◦C (for 18S, IL-6, iNOS and Mannose
Receptor), 64◦C (for TGF-β and FOXP3), 58◦C (for YMI, FIZZ
and RORγt), or 62◦C (for TNF-α). Quantification was performed
using the comparative threshold cycle (Ct) method and the
efficiency of the RT reaction (relative quantity, using the 2−11Ct
method). Replicates were then averaged, and fold induction was
determined considering the value at time 0 as 1 (36).
Primer Sequences
Primer sequences used in this work were designed following the
next protocol:
The database “Nucleotide” (NCBI, NIH, MD, United States)
was used to look for the gene to be amplified. Once the complete
sequence of the target mRNA was found, it was downloaded
in FASTA format.
The sequence was read using the software “Oligo,” v.6
(Molecular Biology Insights, Inc., CO, United States).
Using this software, the following requisites for the custom
primers were set:
• Product length: Between 50 to 300 base pairs.
• Melting temperature for the primers: 58–62◦C.
• Percentage of GC: >50%, to attain some stability.
• The 1G formation: 0 to−3.5 Kcal/mol.
• The primers were searched in the middle of the gene.
Duplex and hairpin formation were analyzed with Oligo v.6
software as well. The custom primers did not create neither the
duplex nor the hairpin, indicating their good quality.
Once the pair of primers for each amplification was
obtained, the specificity was checked in the Genome Browser
(www.genome.ucsc.edu, University of California, Santa Cruz,
CA, United States). After introducing the primer sequences in
the application in silico PCR (www.genome.ucsc.edu, University
of California, Santa Cruz, CA, United States), they showed
only one product for each primer pair, confirming that they
were specific and that all observed genes should correspond
to the one sought.
Then, the position of the primers was searched in the
mRNA. The forward and the reverse primers were located in
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different exons, ensuring that the amplified product was the
mature transcript, after the alternative splicing. This requirement
was studied using the application “BLAST/BLAT search” at
www.ensembl.org (EMBL-EBI, Cambridge, United Kingdom).
The following forward and reverse primer sequences were
used in RTQ-PCR assays to reverse-amplify the mRNA sequences
of the indicated transcription factors, pro-inflammatory
cytokines, and mediators and M2 signature markers. 18S
rRNA was amplified as a house-keeping gene for normalization
purposes:
RORγt Fw: 5′ GCA AGT CCT TCC GAG AGA 3′
Rev: 5′GTG TGG TTG TTG GCA TTG TAG 3′
FOXP3 Fw: 5′TGT TCG CCT ACT TCA GAA ACC AC 3′
Rev: 5′CTC CCT TCT CGC TCT CCA CTC 3′
TNF-α Fw: 5′ CGG GCA GGT CTA CTT TGG AG 3′
Rev: 5′ ACC CTG AGC CAT AAT CCC CT 3′
IL-6 Fw: 5′ TGA TGC ACT TGC AGA AAA CAA 3′
Rev: 5′ GGT CTT GGT CCT TAG CCA CTC 3′
iNOS Fw: 5′ CAC AGC AAT ATA GGA TCA TCC A 3′
Rev: 5′ GGA TTT CAG CCT CAT GGT AAA C 3′
TGF-β Fw: 5′CAC CGG AGA GCC CTG CAT A 3′
Rev: 5′ TGT ACA GCT GCC GCA CAC A 3′
YMI Fw: 5′GGA TGG CTA CAC TGG AGA AA 3′
Rev: 5′AGA AGG GTC ACT CAG GAT AA 3′
FIZZ Fw: 5′ CCC TTC TCA TCT GCA TCT C 3′
Rev: 5′ CAG TAG CAG TCA TCC CAG CA 3′
Mannose Receptor Fw: 5′CAA GGA AGG TTG GCA TTT
GT
Rev: 5′ CCT TTC AGT CCT TTG CAA GC 3′
18S Fw: 5′AAC ACG GGA AAC CTC ACC C 3′
Rev: 5′ CCA CCA ACT AAG AAC GGC CA 3′
Cytokine ELISA
IL-6, IL-17, and TNF-α serum concentrations were measured
using ELISA Kits according to the manufacturer’s instructions
(BD Biosciences OptEIATM and Biolegend). The reaction was
detected by peroxidase-conjugated streptavidin, followed by
incubation with hydrogen peroxide as a substrate and ABTS
(Sigma Aldrich Co., St. Louis, United States) as a chromogen.
Sample cytokine concentrations were interpolated from standard
curves of recombinant IL-6, IL-17, and TNF-α. Absorbance
readings were performed at 405 nm.
Statistical Analysis
The Kaplan–Meyer test was used to analyze differences in
mortality rates between groups. Differences between the infected,
treated or untreated groups, for the several parameters were
analyzed by one-way ANOVA. Comparison of every mean with
every other mean was performed with the Tukey post hoc test.
The Spearman rank-order correlation test was used to evaluate
the correlation between IL-6 serum concentration or IL-6 mRNA
expression and either EF or SF. Differences were considered
statistically significant when p < 0.05. GraphPad Prism version 7
and the open source R Studio software was used for data analysis.
RESULTS
Infection With K98 Induces Cardiac
Dysfunction in IL-10 KO Mice
IL-10 knockout and WT mice were infected with the K98 clone
of T. cruzi, in order to evaluate the role IL-10 on the effects
of fenofibrate treatment in an experimental model of Chagas
disease. Parasitemia was analyzed during the course of infection
in fenofibrate-treated and untreated mice. No differences were
observed between groups. A peak was observed between weeks
5 and 6 pi, decreasing thereafter (Figure 1). Moreover, survival
was unaffected in both mouse genotypes (data not shown). Thus,
lack of IL-10 did not alter the susceptibility of mice to K98
infection. Serum samples were analyzed by ELISA to determine
the levels of IL-10 in uninfected, T. cruzi –infected, and T. cruzi
-infected and fenofibrate-treated WT mice. IL-10 KO mice were
used as controls. As shown in Figure 2, IL-10 levels increased in
the serum of WT mice upon infection with T. cruzi K98 clone.
Moreover, fenofibrate treatment of infected WT mice further
increased this cytokine. On the contrary, IL-10 was undetectable
in sera of IL-10 KO mice.
In order to deepen into the role of IL-10 in the modulatory
effects of fenofibrate, we tested whether there were differences
in the echocardiographic parameters between IL-10 KO and WT
mice. The EF and SF of uninfected IL-10 KO and WT mice did
not show differences (Figure 3A). Then, IL-10 KO and WT mice
were infected with the K98 myotropic clone of the CA-I strain.
The IL-10 KO mice displayed echocardiographic alterations at
week 5 pi (Figure 3B). On the other hand, echocardiographic
parameters of T. cruzi-infected WT mice revealed no significant
differences compared to controls (Figure 3B). After four weeks
of treatment with fenofibrate, infected mice were analyzed by
echocardiography (9 weeks post-infection). Restoration of EF
and SF values to normal were observed in IL-10 KO mice
FIGURE 1 | Parasitemia. Bloodstream parasites were quantified between 3-
and 8-weeks pi, by the method of Pizzi modified by Brener, in infected and
fenofibrate-treated IL-10 KO and WT. N = 7 mice per group. 3 replicate
experiments. Point to point Student t test, mean ± SEM, p = NS.
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FIGURE 2 | Determination of IL-10 concentration in sera. Concentration of
IL-10 was measured by ELISA in sera from uninfected, T. cruzi-infected, and
T. cruzi-infected fenofibrate-treated WT and IL-10 KO mice. Differences
between groups were analyzed by ANOVA (mean ± SEM) followed by Tukey
post hoc test. Differences were considered significant when p < 0.05. N = 7
mice per group, 3 replicate experiments. *p < 0.05 and ***p < 0.001.
(Figure 3C). As expected, no changes in the echocardiographic
parameters were observed in WT mice (Figure 3C).
Fenofibrate Has no Effects on Heart
Inflammatory Infiltrates in IL-10 KO Mice
We have previously reported that fenofibrate significantly
reduces the extension of heart infiltrates in the mixed model
of infection with bloodstream trypomastigotes of the K98 clone
for 6 weeks, and re-infected with bloodstream trypomastigotes
of the virulent RA strain (38). Then, we sought to determine
whether, under IL-10 deficiency conditions, fenofibrate was able
to promote a similar reduction using the single infection model,
since IL-10 KO did not survive the co-infection infection (data no
shown). As shown in Figure 4B the heart of infected IL-10 KO
mice developed a significant interstitial inflammatory response,
that fenofibrate was unable to control. On the other hand, WT
mice developed mild heart infiltrates upon infection with the
K98 clone, regardless of fenofibrate treatment (Figure 4A). Thus,
these results lead to the conclusion that IL-10 is required to
control the extent of the inflammatory infiltrate in the heart. CK
levels were increased at week 9 pi in IL-10 KO mice compared
to controls, and fenofibrate restored CK concentration to normal
values. On the other hand, no changes were observed in WT
mice (Figure 5).
Fenofibrate Reduces Fibrosis in the
Heart of IL-10 KO Mice Infected With
T. cruzi
Fibrosis is a hallmark of progressive heart remodeling during
chronic T. cruzi infection. Since we found that fibrosis was limited
upon treatment with fenofibrate in a previous study using a
mixed T. cruzi infection model (38), heart sections were stained
with picrosirius red to search for collagen deposits in the hearts of
IL-10 KO mice infected with the K98 strain of T. cruzi. Interstitial
fibrosis was observed in tissue sections of the myocardium.
Remarkably, fenofibrate significantly reduced collagen deposits
in infected IL-10 KO mice (Figure 6B). Interestingly, no fibrosis
developed in K98-infected WT mice (Figure 6A). In agreement
with these histopathological findings, the weight of T. cruzi
infected hearts from IL-10 KO mice was significantly higher
than that of WT mice. Moreover, while fenofibrate was able to
reduce the heart weight of IL-10 KO significantly, no differences
were found in WT mice. As a whole, weight reduction could
be ascribed to the diminished fibrotic response upon fenofibrate
treatment (Figure 6C).
We have previously shown that fenofibrate reduces heart
fibrosis and that this phenomenon is accompanied by a decrease
in the levels of the pro-fibrotic factors connective tissue growth
factor (CTGF) and matrix metalloproteinase 9 (MMP 9) (38).
Since TGF-b is a profibrotic factor upstream CTGF (45), we
considered to study its expression at the mRNA level by qRT-
PCR in this organ. TGF-β transcription increased upon infection
of IL-10 KO mice, while no changes were observed in WT mice.
The increased transcription was reduced as a result of fenofibrate
treatment (Figure 6D).
Fenofibrate Modulates Proinflammatory
Mediators Independently of IL-10
We have previously shown that proinflammatory mediators
(NOS2, IL-6, and TNF-α) increase in the heart of mice after
co-infection with T. cruzi strains, and that fenofibrate is able to
modulate this response (38). To determine whether fenofibrate
could exert the same effect in the absence of IL-10 in the single
infection model, we assessed the levels of mRNA expression
of the M1 markers IL-6, TNF-α and NOS2 in knock out
mice. Infection increased their transcription, while treatment
with fenofibrate reduced them significantly (Figures 7A–C,
respectively). On the contrary, mRNA of these markers remained
unchanged independently of the WT mice group (Figures 7A–
C, respectively).
When the concentration of proinflammatory cytokines was
assessed in sera of T. cruzi-infected IL-10 KO and WT mice,
an increase in IL-6 (Figure 7D), TNF-α (Figure 7E), and
IL-17 (Figure 7F) was observed in infected IL-10 KO mice,
while treatment with fenofibrate reduced their concentration
to control values.
The correlation between IL-6 and cardiac dysfunction was
assessed. As shown in Figure 8A, the increase of IL-6 in the
sera of T. cruzi-infected IL-10 KO mice is strongly correlated
with a decrease of either EF or SF. Moreover, the correlations
approached zero upon treatment with fenofibrate. This was
associated with the fact that this drug reduced the levels
of IL-6 and reversed cardiac dysfunction. Besides, there is
no correlation between these parameters in WT mice. The
same results were observed when the correlation between IL-
6 mRNA expression and the functional parameters was studied
(Supplementary Figure 1).
IL-10 Is Required by Fenofibrate to
Promote an M1-to-M2 Bias in Heart
Tissue
Wild-type and IL-10 KO mice were infected with the K98 clone
of T. cruzi and the expression of mRNA of three M2 markers
Frontiers in Immunology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 572178
fimmu-11-572178 September 21, 2020 Time: 17:17 # 6
Rada et al. Fenofibrate Effects Partly Involves IL-10
FIGURE 3 | Echocardiographic studies in IL-10 KO and WT mice. The Ejection fraction and the Shortening fraction were measured by echocardiography in
uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated IL-10 KO and WT mice. (A) Ejection fraction and Shortening fraction measured before infection
in IL-10 KO and WT mice. (B) Ejection fraction and Shortening fraction measured, at week 5, in uninfected and T. cruzi-infected IL-10 KO and WT mice. (C) Ejection
fraction and Shortening fraction measured, at week 9 in uninfected, T. cruzi-infected and T. cruzi-infected and fenofibrate-treated (treatment finished) IL-10 KO and
WT mice. Differences between groups were analyzed by Student t test (mean ± SEM) and ANOVA (mean ± SEM) followed by Tukey post hoc test. 7 mice per
group, 3 replicate experiments. *p < 0.05; ***p < 0.001; and ****p < 0.0001.
was analyzed at the end of fenofibrate treatment (9 weeks pi).
As shown in Figure 9, fenofibrate promoted an increase in the
amount of mannose receptor, YM1, and FIZZ, and mRNAs in the
hearts of WT mice. On the other hand, infection with T. cruzi
in the absence of IL-10 promotes the upregulation of these M2
markers that could not be further increased by fenofibrate. This
suggests that IL-10 deficiency is circumvented by compensatory
mechanisms to drive M1-to-M2 bias in T. cruzi-infected mice.
Fenofibrate Modulates RORγt
Expression Independently of IL-10
To deepen into the anti-inflammatory mechanism of fenofibrate
in the model of CHD, we analyzed the capability of the PPARα
ligand both to modify the expression of RORγt and FOXP3,
since cells expressing these transcription factors are primarily
committed to differentiate into Th17 and Treg cells, respectively.
Consistent with the increase in serum IL-17 (Figure 7F),
augmented expression of RORγt was observed in the heart of
T. cruzi-infected mice, irrespectively of the expression of IL-10,
while fenofibrate treatment could modulate RORγt expression
(Figure 10A). Hence, these results would demonstrate that
fenofibrate is able to regulate the differentiation of Th17 cells
by precluding the expression of its master transcription factor.
Moreover, no changes in the expression of FOXP3 were observed
in IL-10 KO or in WT mice (Figure 10B).
DISCUSSION
Although the mechanisms that lead to the development of CCC
are still intriguing due to the fact that not all infected patients
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FIGURE 4 | Inflammatory reaction in the heart. Histological sections of the heart of uninfected (left panel), T. cruzi-infected (center panel), and T. cruzi-infected
fenofibrate-treated (right panel), WT (A) and IL-10 KO (B) mice. Bar graphs: infiltrate score quantification. Differences between groups were analyzed by ANOVA
(mean ± SEM) followed by Tukey post hoc test. 7 mice per group, 3 replicate experiments. **p < 0.01.
FIGURE 5 | Serum Creatinine Kinase. CK activity was measured in the serum
of uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated WT
and IL-10 KO mice using a colorimetric assay. Differences between groups
were analyzed by Student t test and ANOVA followed by Tukey post hoc test.
Differences between groups were analyzed ANOVA (mean ± SEM) followed by
Tukey post hoc test. Differences were considered significant when p < 0.05. 7
mice per group, 3 replicate experiments. **p < 0.01 and ***p < 0.001.
develop heart anomalies, the relevance of parasite persistence as
a trigger is presently acknowledged (8–10, 46–48). However, the
understanding of the involvement of the different components
of the inflammatory response and CCC is still unclear. This
has led to attempts to treat the chronic stage of the disease
solely based on the use of anti-parasitic drugs (49–51). Current
evidence from experimental and human cases, however, shows
almost invariably that the unrestrained inflammatory response
is, at least in part, associated with the outcome of the disease. In
this regard, several researchers have shown increased expression
of pro-inflammatory cytokines in serum as well as in tissue in
different experimental models of Chagas disease (52, 53), as
well as associations between the increase in their concentration
during the acute stage of the disease and the loss of contractile
capability of myofibers during the chronic phase (54). Others
have shown elevated pro-inflammatory cytokines in serum and
heart sections of patients with CCC in comparison with patients
with chronic asymptomatic infection (55–58). Interestingly, SNP
polymorphisms in the genes encoding for pro-inflammatory
cytokines, are involved in variations in serum concentration of
the coded cytokines and might be related to the progression
of CCC (59). These findings pose the question as to whether
treatments based on the combination of drugs that modulate
the inflammatory response in conjunction with the presently
available anti-parasitic treatment, would be a better approach
for the treatment of CCC and other chronic parasitic diseases
with a significant inflammatory component. Taking all this into
account, our group has led research on the effect of different
PPAR agonists in the context of Chagas disease (38, 60–63),
that bear in common anti-inflammatory properties besides their
effect on carbohydrate (PPARγ) or lipid (PPARα) metabolism.
We have recently shown that BALB/c mice co-infected with two
T. cruzi strains and treated benznidazole, in combination with
fenofibrate, leads to better heart function and reduction of pro-
inflammatory cytokines, infiltrated heart cells, and fibrosis than
mice untreated with the fibrate (38). While the exact mechanisms
involving such improvements were not fully understood, some
clues were derived from studies conducted in human beings.
It has been reported that patients with asymptomatic Chagas
disease express higher levels of IL-10 than CCC patients (59,
64, 65). Therefore, we sought to determine the role of IL-10 in
the anti-inflammatory effects of fenofibrate. For this purpose,
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FIGURE 6 | Heart remodeling and fibrosis. Whole hearts where perfused, excised, and weighted. Fibrosis was evaluated in heart sections of uninfected (left panels),
T. cruzi-infected (center panels), and T. cruzi-infected fenofibrate treated WT (A) and IL-10 KO (B) mice were stained with picrosirius red. Bar graphs to the right:
quantitative analysis of fibrosis. (C) Heart/body weight ratio was evaluated in uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated IL-10 KO and WT
mice. (D) The expression of TGF-β was determined by qRT-PCR in heart homogenates of uninfected, T. cruzi-infected and T. cruzi-infected fenofibrate-treated IL-10
KO and WT mice. Differences between groups were analyzed by ANOVA (mean ± SEM) followed by Tukey post hoc test. Differences were considered significant
when p < 0.05. 7 mice per group, 3 replicate experiments. *p < 0.05; **p < 0.01; and ***p < 0.001.
we took advantage of IL-10 KO mice. Treatment of these mice
with fenofibrate alone ameliorated the cardiac function. This
strongly suggests that the anti-inflammatory effects of this drug
are, at least in part, independent of IL-10 and, secondly, unrelated
to the parasite load. In fact, we have previously shown that
fenofibrate does not alter parasitemia or tissue parasitism in a
mixed infection murine model of chronic CHD (38).
Given the fact that fenofibrate might play different roles that
would or would not depend on IL-10 expression, we assessed
the levels of IL-10 in uninfected, T. cruzi-infected, and T. cruzi
-infected and fenofibrate-treated WT and IL-10 KO mice. IL-
10 increased upon T. cruzi infection in WT mice. Moreover,
treatment of WT mice with fenofibrate increased IL-10 levels
further. Notably, the absence of this cytokine in IL-10 KO mice,
correlated with increased infiltrate extension in the heart.
These findings support the fact that IL-10 is required to
modulate heart tissue infiltration and that, contrary to what
happens in the mixed infection model of WT mice (38),
fenofibrate is unable to exert this role in IL-10 KO mice. However,
this effect may be probably hindered by the fact that heart
infiltration is scarce due to the low virulence of the T. cruzi K98
clone, in the single strain infection model of WT mice.
The ongoing inflammatory response together with the local
expression of pro-inflammatory mediators like IL-6, IL-17, TNF-
α, and NOS2 contributes to tissue damage. Associated with
this, we observed that, lack of IL-10 promotes severe cardiac
dysfunction that correlates with increased IL-6 production.
Moreover, fenofibrate is able to mitigate this effect (Figure 8). The
inflammatory response subsequently drives tissue remodeling
involving fibroblast proliferation and collagen deposition. In
the experimental model analyzed in this work, fenofibrate was
able to reduce the expression of pro-inflammatory mediators
and fibrosis regardless of IL-10 expression. This phenomenon
was associated with the capability of fenofibrate to reduce the
transcription of TGF-β, which is the main regulator of fibrosis
(66). Besides, it has been documented that this cytokine is
involved in heart remodeling by altering the pattern of secretion
of MMP, collagen, fibronectin, and other contributing fibrogenic
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FIGURE 7 | Assessment of the expression and concentration of proinflammatory mediators. Expression of IL-6 (A), TNF-α (B), and NOS2 (C) was determined by
qRT-PCR in heart homogenates of uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated WT and IL-10 KO mice. Concentration of IL-6 (D), TNF-α
(E), and IL-17 (F) was measured in sera from uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated WT and IL-10 KO mice. Differences between
groups were analyzed by ANOVA (mean ± SEM) followed by Tukey post hoc test. Differences were considered significant when p < 0.05. 7 mice per group, 3
replicate experiments. *p < 0.05; **p < 0.01; and ***p < 0.001.
mediators (67). Interestingly, heart remodeling involving fibrosis
is associated with high TNF-α and TGF-β expression (68).
Thus, fenofibrate would act in two arenas to preclude its
pathological consequences, simultaneously reducing TGF-β and
TNF-α and, as we show in this manuscript, these effects are
independent of IL-10 production. Despite the fact that TGF-
β transcription remains unaffected in WT, IL-10 might play
a role favoring non-pathogenic heart remodeling, since it has
been shown to promote M1-to-M2 macrophage polarization
and hyaluronan degradation in a mouse model of myocardial
infarction (34). Interestingly, while infected WT mice display
a clear M1-to-M2 polarization that is further increased by
fenofibrate, their IL-10 KO counterparts do not. Significantly,
WT polarization was associated with the increase of mannose
receptor and Ym1 expression, while FIZZ expression was
unaffected. In this regard, Atochina et al. (69), reported that
the glycan LNFPIII rapidly upregulates Arg1 and Ym1 on
macrophages. However, LNFPIII-activated macrophages did not
show upregulation of other alternatively activated macrophage
markers, like FIZZ-1, MGL-1, and MMR in vivo. Similar
results were shown by Osada et al. (70) upon infection of
streptozotocyn-induced diabetic mice with Schistosoma mansoni.
Since FIZZ-1 increases in WT mice in our model, we can
hypothesize that IL-10 is required for FIZZ-1 upregulation.
In our CHD model, IL-10 KO mice treated with fenofibrate
do not display any M1-to-M2 bias, which is crucial to
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FIGURE 8 | Relationship between cardiac disfunction and IL-6. Spearman rank-order correlation test between ejection fraction (A) or shortening fraction (B) and
concentration of IL-6 in sera from uninfected, T. cruzi-infected, and T. cruzi-infected and fenofibrate-treated WT and IL-10 KO mice were made. Spearman
correlation coefficient is reported for each of the correlations.
FIGURE 9 | Effect of T. cruzi infection and fenofibrate treatment on the expression of M2 markers. The level of transcription of Mannose Receptor (A), Ym1 (B), and
Fizz (C) was determined by qRT-PCR in heart homogenates from uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated WT and IL-10 KO mice.
Differences between groups were analyzed by ANOVA (mean ± SEM) followed by Tukey post hoc test. Differences were considered significant when p < 0.05. 7
mice per group, 3 replicate experiments. *p < 0.05 and **p < 0.01.
control the process of heart remodeling. However, under IL-
10 deficiency conditions, fenofibrate is still able to reduce
TGF-β transcription, thereby limiting collagen accumulation
in heart tissue, as observed in the histological sections.
Moreover, we found that the reduced expression of pro-
inflammatory cytokines and TGF-β was associated with heart
function amelioration. Similarly, a reduction in serum TGF-
β concentration through pharmacological treatment associated
with heart function improvement has been observed by
others (71).
A recent work suggests that a worse clinical progression of
CCC is associated with increased serum IL-17 and of alternative
Th17 cell frequency (72). However, other authors have observed
positive correlation between the levels of IL-17A and LV ejection
fraction, suggesting IL-17A elevation is a good prognostic marker
for CCC (73). In spite of this, treatment of C57Bl/6 mice with
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FIGURE 10 | Expression of RORγt and FOXP3 in IL-10KO and WT mice. The level of transcription of RORγt (A) and FOXP3 (B) mRNA was determined by qRT-PCR
in heart homogenates from uninfected, T. cruzi-infected, and T. cruzi-infected fenofibrate-treated WT and IL-10 KO mice. Differences between groups were analyzed
by ANOVA (mean ± SEM) followed by Tukey post hoc test. Differences were considered significant when p < 0.05. 7 mice per group, 3 replicate experiments.
**p < 0.01 and ***p < 0.001.
FIGURE 11 | Fenofibrate exerts IL-10 dependent and IL-10 independent effects. The reduction of the inflammatory infiltrate extension and the increase in the
expression of M2 markers are IL-10-dependent effects of fenofibrate, while the reduction of proinflammatory mediators expression, cardiac fibrosis and the
restoration of cardiac function are IL-10 independent effects.
an anti-TNF-α monoclonal antibody (InfliximabTM) reduced
the frequency of IL-17A+ and increased the frequencies of
IL-10+ CD4 T cells, and also augmented IL-10+Ly6c+ and
F4/80+ cells. This treatment ameliorated cardiac function and
remodeling (53), thus suggesting a deleterious role of IL-17 in
the mouse model.
Since we found that improvement of heart dysfunction
and inflammatory response is associated with the inhibition
of IL-17 and RORγt expression, it may be considered that
fenofibrate treatment results in a better outcome through
inhibition of Th17 cells. Besides IL-17, the expression of other
pro-inflammatory cytokines, like IL-6, and TNF-α, decreases
upon treatment with fenofibrate. In this regard, it has been
reported that fenofibrate reduces colitis induced by dextran
in IL-10KO C3H/HeJB mice, and this effect is due to the
inhibition of IL-17 expression (74). Since both IL-6 and TGF-β
are required for Th17 cell differentiation, it would be possible
that fenofibrate precludes Th17 differentiation by limiting their
concentration. In fact, the reduced concentration of IL-17
observed in serum of mice after fenofibrate treatment was
associated with a significant reduction in the transcription of
RORγt, the master regulator for Th17 cell differentiation. In
this regard, the inhibition of in vitro differentiation of Th17
by fenofibrate treatment has been reported previously (75).
Moreover, this inhibition has been shown to play a beneficial
role in an experimental model of dextran-induced colitis (74)
and in an experimental model of autoimmune myocarditis in
mice and rats (76). Interestingly, FOXP3 expression remained
unchanged after treatment with fenofibrate, suggesting that
this drug mainly exerts its anti-inflammatory effects through
the modulation of the pro-inflammatory branch. However, our
results differ from those observed by Zhou et al. (77), showing
the ability of fenofibrate to promote in vitro differentiation of
Treg cells and those by Chang et al. (76), who show increased
expression of FOXP3 in the hearts of rats with experimental
autoimmune myocarditis, after fenofibrate treatment. This
disagreement could be attributed to several factors, including
the genetic background of mice used for these studies and
the etiology of the pathological condition (autoimmune vs.
infectious) analyzed.
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In conclusion, our results show that in the absence of IL-
10, fenofibrate is able to ameliorate the heart function of
T. cruzi-infected mice inducing the modulation of IL-17, among
other cytokines, and preventing the development of fibrosis.
Furthermore, our results emphasize that IL-10 is required to
promote a healing profile in the heart, characterized by the
expression of M2 markers (Figure 11). These findings may prove
useful to design combined therapies that not only reduce the
parasite burden but simultaneously lessen the noxious effects of
the persistent inflammatory response.
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